摘要
目的探讨高血压并冠心病患者治疗中给予厄贝沙坦治疗的临床效果及对血管内皮细胞功能、炎性因子的影响。方法选取2020年4月至2022年3月期间我院收治的高血压合并冠心病患者180例展开研究,随机分为两组并给予不同治疗方案。观察两组治疗前后血压水平、血管内皮细胞功能以及炎性因子水平,并对比两组疗效及不良反应。结果治疗后,实验组收缩压(124.12±8.14)mmHg、舒张压(76.15±4.34)mmHg以及平均动脉压水平(74.28±7.25)mmHg,均低于参照组的(133.45±9.46)mmHg、(88.45±5.26)mmHg、(96.64±10.24)mmHg,P<0.05。实验组一氧化碳(112.12±17.14)mg/L高于参照组的(90.45±15.46)mg/L,而内皮素-1(41.15±6.34)mg/L低于参照组的(55.45±7.26)mg/L,P<0.05。实验组TNF-α(7.12±2.14)ng/L、IL-6(12.15±3.34)ng/L以及CPR(3.28±1.25)mg/L均低于参照组的(11.45±3.46)ng/L、(18.45±4.26)ng/L、(5.64±1.24)mg/L,P<0.05。实验组治疗有效率为92.22%,显著高于参照组的71.11%,P<0.05。实验组不良反应发生率为8.89%,稍低于参照组的14.44%,组间差异无统计学意义,P>0.05。结论针对高血压合并冠心病患者,给予厄贝沙坦治疗更有利于控制患者血压,改善患者血管内皮细胞功能,降低机体炎性反应,且疗效更加确切,值得推广。
Objective To study the treatment of the patients with hypertension and coronary heart disease(CHD)for Mr The clinical effect of treatment and the influence on vascular endothelial cell function and inflammatory factor.Methods To choose between April 2020 and March 2022 our hospital during the period of hypertension combined the study of 180 cases of patients with coronary artery disease,were randomly divided into two groups and given different treatment options.Observe two groups before and after treatment the blood pressure level,vascular endothelial cell function and inflammatory factor levels,and compared two groups of curative effect and adverse reactions.Results After treatment,systolic blood pressure(124.12±8.14)mmHg,diastolic blood pressure(76.15±4.34)mmHg and mean arterial blood pressure(74.28±7.25)mmHg,All lower than the reference group(133.45±9.46)mmHg,(88.45±5.26)mmHg and(96.64±10.24)mmHg,P<0.05.The carbon monoxide(112.12±17.14)mg/L in the experimental group was higher than that in the reference group(90.45±15.46)mg/L,while the endothelin-1(41.15±6.34)mg/L was lower than the reference group(55.45±7.26)mg/L,P<0.05.TNF-α(7.12±2.14)ng/L,IL-6(12.15±3.34)g/L and CPR(3.28±1.25)mg/L were lower than the reference group(11.45±3.46)ng/L,(18.45±4.26)ng/L and(5.64±1.24)mg/L P<0.05.The experimental treatment effective rate was 92.22%,significantly higher than that of control group 71.11%,P<0.05.Experimental group the incidence of adverse reactions was 8.89%,slightly less than 14.44%of the control group,there was no statistically significant difference between the groups,P>0.05.Conclusion In the treatment of patients with hypertension combined with coronary heart disease,irbesartan is more beneficial to control the blood pressure of patients,improve the function of vascular endothelial cells in patients,reduce the inflammatory response of the body,and the curative effect is more accurate,worthy of promotion.
作者
种小娟
姬劲锐
ZHONG Xiao-juan;JI Jin-rui(Zhengzhou Renlu Community Health Service Center,Zhengzhou 450052,Henan Province,China;Zhengzhou People's Hospital,Zhengzhou 450053,Henan Province,China)
出处
《罕少疾病杂志》
2023年第5期44-45,56,共3页
Journal of Rare and Uncommon Diseases
关键词
厄贝沙坦
高血压
冠心病
血管内皮细胞功能
炎性因子
Irbesartan
High Blood Pressure
Coronary Heart Disease
Vascular Endothelial Cell Function
Inflammatory Factor
